Prof Finn talks to ecancer at at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about the results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for firstline treatment of ER+/HER2- advanced breast cancer.

The new compound has the potential to be a standard of care in this setting, if a phase 3 study is successful, and also has promise in the adjuvant setting.

Filming Supported by Amgen